161 related articles for article (PubMed ID: 17482465)
41. Molecular analysis of nipple fluid for breast cancer screening.
Suijkerbuijk KP; van der Wall E; Vooijs M; van Diest PJ
Pathobiology; 2008; 75(2):149-52. PubMed ID: 18544970
[TBL] [Abstract][Full Text] [Related]
42. Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.
Sauter ER; Tichansky DS; Chervoneva I; Diamandis EP
Environ Health Perspect; 2002 Mar; 110(3):241-6. PubMed ID: 11882474
[TBL] [Abstract][Full Text] [Related]
43. Detection of 2,6-cyclolycopene-1,5-diol in breast nipple aspirate fluids and plasma: a potential marker of oxidative stress.
Chen G; Djuric Z
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1592-6. PubMed ID: 12496049
[TBL] [Abstract][Full Text] [Related]
44. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
45. Breast-tissue sampling for risk assessment and prevention.
Fabian CJ; Kimler BF; Mayo MS; Khan SA
Endocr Relat Cancer; 2005 Jun; 12(2):185-213. PubMed ID: 15947097
[TBL] [Abstract][Full Text] [Related]
46. Analysis of aluminium content and iron homeostasis in nipple aspirate fluids from healthy women and breast cancer-affected patients.
Mannello F; Tonti GA; Medda V; Simone P; Darbre PD
J Appl Toxicol; 2011 Apr; 31(3):262-9. PubMed ID: 21337589
[TBL] [Abstract][Full Text] [Related]
47. Methodological considerations in estrogen assays of breast fluid and breast tissue.
Chatterton RT; Muzzio M; Heinz R; Gann PH; Khan SA
Steroids; 2015 Jul; 99(Pt A):103-7. PubMed ID: 25159105
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
49. Influence of lactation history on breast nipple aspirate fluid yields and fluid composition.
Djuric Z; Visscher DW; Heilbrun LK; Chen G; Atkins M; Covington CY
Breast J; 2005; 11(2):92-9. PubMed ID: 15730453
[TBL] [Abstract][Full Text] [Related]
50. Clinical implications of prostate-specific antigen in men and women.
Yu H
J Gend Specif Med; 2000; 3(2):45-8, 53. PubMed ID: 11253246
[TBL] [Abstract][Full Text] [Related]
51. Effects of high fruit-vegetable and/or low-fat intervention on breast nipple aspirate fluid micronutrient levels.
Djuric Z; Chen G; Ren J; Venkatramanamoorthy R; Covington CY; Kucuk O; Heilbrun LK
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1393-9. PubMed ID: 17627004
[TBL] [Abstract][Full Text] [Related]
52. Non-steroidal anti-inflammatory drug (NSAID) use and levels of a lipid oxidation marker in plasma and nipple aspirate fluids.
Kato I; Chen G; Djuric Z
Breast Cancer Res Treat; 2006 May; 97(2):145-8. PubMed ID: 16322889
[TBL] [Abstract][Full Text] [Related]
53. Nipple fluid basic fibroblast growth factor in patients with breast cancer.
Sartippour MR; Zhang L; Lu M; Wang HJ; Brooks MN
Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2995-8. PubMed ID: 16365024
[TBL] [Abstract][Full Text] [Related]
54. Does the new automated "HALO" nipple aspiration fluid system really deliver as promised? The answer is "No, but...": A literature review of the role of breast fluid cytology in cancer risk assessment.
Elsheikh TM
Diagn Cytopathol; 2009 Sep; 37(9):699-704. PubMed ID: 19530102
[TBL] [Abstract][Full Text] [Related]
55. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
56. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
[TBL] [Abstract][Full Text] [Related]
57. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
58. Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?
Palmieri C; Gojis O; Rudraraju B; Cleator S
J Clin Oncol; 2008 Dec; 26(35):5824; author reply 5825-6. PubMed ID: 19001345
[No Abstract] [Full Text] [Related]
59. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
60. The local hormonal environment and related biomarkers in the normal breast.
Khan SA; Bhandare D; Chatterton RT
Endocr Relat Cancer; 2005 Sep; 12(3):497-510. PubMed ID: 16172189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
